November 1, 2018
SA Drug Development Company Reaches Major Milestone.
Click here to read more
September 19, 2018
Rapamycin Holdings Treats First Humans in eRapa Clinical Trial.
Click here to read more
May 10, 2018
San Antonio Biotech Moving Potential Cancer Drug Closer to Market.
Click here to read more
May 10, 2018
Rapamycin Holdings Plans Tests of eRapa for Prostate Cancer.
Click here to read more
October 17, 2017
Rapamycin Holdings Obtains Key Patent Approval in Path to Market.
Click here to read more
August 7, 2017
New Rapamycin CEO Hired to Handle Funding, FDA Inflection points.
Click here to read more
July 21, 2017
Rapamycin Holdings hires new CEO as its drug approaches human trials.
Click here to read more
July 11, 2017
Meet the new CEO tasked with taking SA drug developer’s first human product to market.
Click here to read more
April 5, 2016
Drug designed in San Antonio fights age-related diseases.
Click here to view the PDF
October 5, 2015
San Antonio Biotech Firm Seeks Major Funding.
Click here to read more
July 17, 2015
Rapamycin Holdings Seeks FDA approval to treat feline stomatitis.
Click here to read more
June 8, 2015
San Antonio drug developer Rapamycin scores critical funding.
Click here to read more